All In Biotech

Drug Trial Radar · NCT00429273

Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder

An Eight-Week, Randomized, Double-Blind Comparison of Guanfacine, Focalin XR, and the Combination, With a Twelve Month Open-Label Extension for the Treatment of ADHD in Pediatric Subjects Aged 7 to 14 Years

Last checked: Nov 19, 2026Latest source record: Jul 30, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 212 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

212

Actual

Start

Jan 2007

Primary completion

Jul 2011

Study completion Jul 2011

Sponsor

Lead sponsor
University of California, Los AngelesAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Mental Health (NIMH)
First posted
Jan 31, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 7 years, up to 14 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the effectiveness of a single drug versus a combination of drugs in treating attention deficit hyperactivity disorder in children.

Conditions

  • Attention Deficit Disorder With Hyperactivity

Interventions

  • GuanfacineDrug

    Week 1: 0.5 mg twice daily; Week 2: 1 mg twice daily; Week 3: 1.5 mg twice daily; Weeks 4 through 8: best dose as determined by efficacy measures

  • Methylphenidate (MPH)Drug

    Participants less than 25 kg will receive 10 mg once daily for Week 5, 20 mg once daily for Week 6, and 30 mg once daily for Week 7. Subjects greater than 25 kg will receive 20 mg once daily for Week 5, 30 mg once daily for Week 6, 40 mg once daily for Week 7, and best doses as determined by efficacy measures for Week 8.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ADHD IV Rating Scale (Attention Deficit Hyperactivity Disorder Rating Scale)Time frame: Measured at baseline Week 4 and Week 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of California Los Angeles

    Los Angeles, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.